



PULMONOLOGY

www.journalpulmonology.org



REVIEW

Infections in lung transplanted patients: A review

M. Dettori^{a,1}, N. Riccardi^{b,c,1}, D. Canetti^{b,d,1}, R.M. Antonello^{e,1}, A.F. Piana^a,
A. Palmieri^a, P. Castiglia^a, A.A. Azara^a, M.D. Masia^a, A. Porcu^a, G.C. Ginesu^a,
M.L. Cossu^a, M. Conti^a, P. Pirina^a, A. Fois^a, I. Maida^a, G. Madeddu^a, S. Babudieri^a,
L. Saderi^a, G. Sotgiu^{a,b,*}

^a Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy

^b StopTB Italia Onlus, Milan, Italy

^c Department of Clinical and Experimental Medicine, University of Pisa, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

^d Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

^e Clinical Department of Medical, Surgical and Health Sciences, Trieste University, Trieste, Italy

Received 2 May 2021; accepted 25 April 2022

Available online xxx

KEYWORDS

Transplant;
Lungs;
Infections;
Viruses;
Bacteria;
Fungi

Abstract Lung transplantation can improve the survival of patients with severe chronic pulmonary disorders. However, the short- and long-term risk of infections can increase morbidity and mortality rates.

A non-systematic review was performed to provide the most updated information on pathogen, host, and environment-related factors associated with the occurrence of bacterial, fungal, and viral infections as well as the most appropriate therapeutic options.

Bacterial infections account for about 50% of all infectious diseases in lung transplanted patients, while viruses represent the second cause of infection accounting for one third of all infections.

Almost 10% of patients develop invasive fungal infections during the first year after lung transplant. Pre-transplantation comorbidities, disruption of physical barriers during the surgery, and exposure to nosocomial pathogens during the hospital stay are directly associated with the occurrence of life-threatening infections.

Empiric antimicrobial treatment after the assessment of individual risk factors, local epidemiology of drug-resistant pathogens and possible drug-drug interactions can improve the clinical outcomes.

© 2022 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author at: Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
E-mail address: gsotgiu@uniss.it (G. Sotgiu).

¹ These authors contributed equally to this work.

<https://doi.org/10.1016/j.pulmoe.2022.04.010>

2531-0437/© 2022 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The rising prevalence of some severe chronic medical conditions has increased the demand for organ transplantations worldwide. Lung transplantation (LT) has saved the lives of patients suffering from severe pulmonary diseases. However, immunodeficiency following the exposure to immunosuppressive drugs, prescribed to reduce the probability of rejection, increases the risk of acquiring life-threatening infections. Host-related biological agents and environmental factors can affect the infectious risk.

To better define the risk factors and the management of pulmonary infections in lung transplant recipients (LTRs) we performed a narrative review.

Methods

A narrative review was carried out to retrieve the scientific evidence on bacterial, viral, and fungal infections occurring in lung transplant recipients. The search engine Pubmed was used to select peer-reviewed articles published from 1/Jan/2010 to 31/Dec/2021. The References of the selected manuscripts were carefully assessed to collect articles not included in the primary search. The following key-words were used: “lung transplantation”, “infection”, “viral infection”, “bacterial infection”, and “fungal infection”. A total of 344 records were found. Based on titles, abstracts, and the content of the full texts, a total of 108 studies were deemed suitable. Twenty-three (21.3%) were focused on viral infections and lung transplantation, fifty-nine (54.6%) on bacterial infections, twenty (18.5%) on fungal infections, and six (5.6%) on parasitic infections (Fig. 1).

Bacterial infections

Bacterial infection in LT recipients

Bacterial infections are the most frequent infectious complications following LT, accounting for ~50% of all incident

infectious diseases. Pneumonia represents the most frequent bacterial infectious disease after LT.¹

The host predisposing factors and LT predisposing factors

Pre-transplantation comorbidities or medical conditions of the LTR should be carefully considered when the risk of post-LT bacterial infections is computed: patients with cystic fibrosis (CF), diabetes mellitus, obesity or malnutrition, viral hepatitis, human immunodeficiency virus (HIV) infection, latent tuberculosis infection (LTBI), colonization by multi-drug-resistant (MDR) bacteria, chronic renal failure, and the need for mechanical ventilation are all risk factors for post-transplant bacterial infections.²

Moreover, immediately after surgery, LTRs are affected by a complete disruption or partial loss of physical barriers and are at risk of the following medical conditions: aspiration pneumonia, central line-associated bloodstream infection (CLABSI), ureteral catheter-associated infection, *Clostridioides difficile* colitis, and sepsis.²

During the early post-LT period (a few days to 1 month later), nosocomial microorganisms account for the majority of infections; LTRs with CF are more likely to develop colonization and recipient- or donor-harbored infection infection by *Pseudomonas aeruginosa*, non-tuberculous mycobacteria (NTM), and *Burkholderia cepacia* complex.^{2,3}

LT procedures associated with a transient disruption of the bronchial circulation may cause the loss of the epithelial integrity, as well as ciliary function and mucus production, increasing the risk of infection.^{2,4}

Denervation of the allograft may suppress the cough reflex, promoting bacterial colonization and bronchial inflammation.⁵ Impaired lymphatic drainage of the allograft may result in stasis and oedema of the bronchial tissues, slowing normal healing and promoting superinfection.⁵

In the case of necrosis of the bronchial anastomosis, bacterial colonization can increase due to a reduced clearance of secretions.⁵

Immunosuppression, as well as the type of immune-suppressant agents, to prevent reject of the allograft may lead to prolonged T- and B-cell dysfunction, and/or macrophage and cytokine dysregulation (mainly caused by corticosteroids), exposing LTRs to the risk of bacterial pathogens (e.g., *Nocardia spp.*, *Mycobacterium tuberculosis*).

Epidemiology of bacterial infection post LT

Bacterial infections, mainly located in the respiratory tract, are more frequent in LTRs than in other solid organ transplant (SOT) recipients: 35%–66% of the infections in LTRs are caused by bacteria, with 50–85% of recipients showing a bacterial complication after transplantation.^{2,6,7}

LTRs may experience >1 bacterial infection with >1 bacterial pathogen.^{5,8} The risk is highest during the first 3 weeks after LT, with *P. aeruginosa*, *Enterobacterales*, *Staphylococcus aureus*, and *Enterococcus* spp. being the most incident pathogens.^{9,10}

However, infections caused by *Acinetobacter* spp., *Stenotrophomonas maltophilia*, and other Gram-negatives are often diagnosed.

The prescription of antibiotic prophylaxis has postponed the occurrence of most cases of bacterial pneumonia to the intermediate and late postoperative period,⁵ including




Fig. 1 Flow diagram of search procedure for narrative review.

tuberculosis (TB) if LTBI is not treated after the LTBI diagnosis.¹¹ NTM disease rate, caused mainly by *Mycobacterium avium* complex, followed by *Mycobacterium abscessus*, is higher among LTR than in the other SOT recipients.^{12,13}

Clostridioides difficile infection, with a highest incidence during the first month after LT, is associated with the use of antibiotics, proton-pump inhibitors (PPIs), and steroids in the immediate pre-LT period.^{14–16}

Screening and antibiotic prophylaxis in LT recipients

Pre-LT

Screening for infections of transplant candidates and living donors is essential to increase the probability of LT success. Vaccinations can help prevent bacterial infections (e.g. *Streptococcus pneumoniae*).

Medical history should be carefully evaluated: previous infections and their therapy, comorbidities, lifestyle, travel history, allergy, contact with TB patients, exposure to antibiotics, animal, and environmental pathogens can help tailor antibiotic prophylaxis.¹⁷ Colonization by MDR Gram negative and positive bacteria should be investigated before transplantation; therefore, rectal (*K. pneumoniae* producing extended-spectrum β -lactamase (ESBL), metallo- β -lactamase (MBL), carbapenem-resistant (KPC)), *E. coli* (ESBL, KPC, MBL), *P. aeruginosa* (MDR), *Acinetobacter* spp. (MDR), *Enterobacter* spp. (MDR), *S. maltophilia*, *Enterococcus* spp. (vancomycin resistant Enterococci VRE)) and nasal swabs (methicillin-sensitive *Staphylococcus aureus* (MSSA), methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin intermediate *Staphylococcus aureus* (VISA)), as well as respiratory cultures, are needed to decrease the risk of a difficult-to-treat infection. Unfortunately, colonization or previous or active infection caused by *Burkholderia cepacia* complex and *M. abscessus* are associated with poor post-transplant outcome: their occurrence could constitute a contraindication for transplantation.^{18–20} Serological testing for some sexually transmitted diseases (e.g., syphilis) should be performed in both transplant candidates and living donors.¹⁹ Donors suspected of having TB should not be considered, whereas LTRs should be screened for LTBI with the interferon-gamma release assay (IGRA) and, if tested positive, a chest-X-ray and molecular, microscopic, and culture and drug susceptibility testing on sputum samples should be performed to exclude active TB.¹⁹ If TB or LTBI is diagnosed, the patient should be immediately treated.²¹

Surgical site infections (soft tissue infection and/or mediastinitis and/or airway anastomosis infection) may occur in ~20% of LTRs.^{22,23} If the pre-LT screening is negative, cefazolin can be prescribed for prophylaxis and should be administered 1 h before incision²³; in the case of an allergy to penicillin, levofloxacin could be an alternative option.²³ On the other hand, if MDR pathogens are detected during screening, the choice of antibiotic should depend on the drug susceptibility profile and on the risk factors for surgical site infection (e.g., if MRSA is detected, linezolid or vancomycin can be coupled with an antibiotic against Gram negatives).²³

The optimal duration of prophylaxis is yet to be elucidated; however, American Society of Transplantation guidelines recommend their prescription for 48–72 h.²³

Trimethoprim-sulfamethoxazole is administered to reduce the incidence of *Pneumocystis jirovecii*, *Nocardia* spp., and *Listeria monocytogenes* infections.²⁴

Post-LT

Blood stream infections (BSI) caused by *Staphylococcus aureus* and *Pseudomonas aeruginosa* may result in early post-transplant sepsis or mycotic aneurysm at the site of allograft vascular anastomoses; therefore, blood cultures should be performed and empiric antibiotics should be prescribed.²⁵

Pneumonia can be diagnosed in the late post-LT period and it can be health care-associated (potentially caused by MDR pathogens) or community-acquired (CAP).²⁶

During a median follow-up of 1.3 years after LT, 6.4% developed invasive infection by *S. pneumoniae*, highlighting the importance of routine pneumococcal vaccination.²⁶

Fig. 2 sums up epidemiology, risk factors, and prevention of bacterial infections in patients with LT.

Reasoned-empirical antibiotic therapy in LT

Empirical antibiotic therapy should be tailored on patients' characteristics: previous allergy to antibiotics, potential drug–drug interactions, bacterial colonization (MDR pathogens) or previous infections, and local epidemiology (hospital where the LT is performed and where the donor lives).^{5,27} A diagnostic work-up with blood cultures and, in the case of respiratory symptoms or signs, bronchoscopy, bronchoalveolar lavage (BAL), and transbronchial lung biopsy should be performed before any antibiotics are prescribed. Following the collection of samples for cultures, broad-spectrum antibiotics can be administered and, when the bacteriological results are known, specific antibiotics can replace the initial therapy.^{5,27,28} Therapeutic drug monitoring (TDM) should be performed to assess the blood concentration of antibiotics and to reduce the risk of side effects.

Pseudomonas spp

LTRs with a history of *P. aeruginosa* colonization are usually treated with two effective drugs for 2 to 3 weeks after surgery to reduce the risk of pneumonia and allograft colonization.^{29,30}

Systemic colistin with systemic and/or aerosol aminoglycosides (AG) should be cautiously prescribed due to the risk of cumulative nephrotoxicity (and the dosage of AG should be carefully chosen considering renal function) when combined with calcineurin inhibitors for immunosuppression; if drug-susceptibility testing (DST) shows cephalosporin susceptibility, ceftazidime (2g IV q8h) or ceftazidime (2g IV q8h) associated with aerosol or intravenous AG can be administered. Fluoroquinolones and piperacillin/tazobactam (4.5g IV q6h) are effective alternative options. If ESBL-producing *P. aeruginosa* is diagnosed, carbapenems (meropenem 2g IV q8h or imipenem/cilastatin 1g IV q6h) or ceftolozane/tazobactam (3g IV q8h) can be prescribed. In the case of a serine-carbapenem-producing *P. aeruginosa*, ceftazidime/avibactam (2.5g IV q8h) or meropenem-vaborbactam (4g IV q8h) should be preferred in combination with aerosol and intravenous colistin, systemic fosfomycin, or aerosol and intravenous AG.^{5,29,31} If metallo-carbapenemase is




Fig. 2 Bacterial infections in LT. In the first month after LT, in addition to community- and hospital-acquired pneumonia, patients are at higher risk of surgical site infection, central line-associated bloodstream infection, ureteral-catheter infection, sepsis, mycotic aneurysms. Immunosuppression due to transplantation and the antibiotic prophylaxis increases the risk of opportunistic infections and *C. difficile* colitis. In the late post-LT period, tuberculosis reactivation, nontuberculous *Mycobacteria* and *S. pneumoniae* infections are the most frequent bacterial infections. Risk factors and suggestions on how to prevent bacterial infections are shown in the blue box. (Source: authors elaboration).

detected, ceftazidime/avibactam (2.5g IV q8h) in association with aztreonam (2g IV q6h) can be administered. Monotherapy with aerosol and intravenous colistin could be another option.

Future options may be aerosol fluoroquinolones, imipenem/relebactam, cefiderocol, and murepavadin.^{31,32}

Anti-pseudomonal agents can be associated with the following issues: drug-drug interactions (DDIs), allergy, and impairment of renal function and drug volume distribution (e.g., obese patients, septic shock).³³

***Acinetobacter* spp**

Empiric antibiotic treatment aimed to treat *Acinetobacter* spp. should rely on local epidemiology: meropenem (2 g IV prolonged infusion over 3 h every 8 h) can be administered in critically ill patients. After DST results, de-escalation to cefepime (2g IV q8h) should be recommended. However, if pan-resistant *Acinetobacter* is detected, systemic (with loading dose) and aerosol colistin, with or without cefiderocol or meropenem in continuous infusion, can be prescribed.^{31,32,34}

Staphylococcus aureus

Staphylococcus aureus pneumonia or BSI in a LTR should be immediately treated to avoid necrotizing pneumonia.³⁵

Active *S. aureus* screening with nasal swabs before LT is highly recommended to avoid post-LT *S. aureus* infection: pre-transplant *S. aureus* colonization in CF patients undergoing LT increases the risk of post-transplant infection.³⁶

If pre-LT screening did not show MRSA colonization, empiric treatment with cefazolin (2g IV q8h) or oxacillin (2g IV q4h), or linezolid (600 mg IV q12 h) (if penicillin or cefalosporin allergies are reported) can be started.^{37–39} In case of MRSA colonization, ceftaroline (600 mg IV q8h) or linezolid (600 mg IV q12 h) should be preferred.

***Enterococcus* spp**

In the case of an infection caused by ampicillin-susceptible *Enterococcus* spp., ampicillin- or amoxicillin-based combination therapy with ceftriaxone (in case of bacteremia, 2g q24h) or aerosol and systemic AG (pneumonia with or without bacteremia) can be administered.^{40,41} In case of VRE, linezolid (600 mg q12h) or tedizolid (200 mg q24h) should be preferred.⁴⁰

Tuberculosis

The culture-based diagnosis of tuberculosis should be supported by the assessment of the drug resistant patterns, if any.^{42,43} Pulmonary resection can be performed in difficult-to-treat cases.⁴⁴ Ideally, screening for *Mycobacterium*

tuberculosis infection in potential organ donors should be systematically implemented to reduce the risk of transmission.⁴⁵

***Burkholderia cepacia* complex**

Infection caused by *Burkholderia cepacia* complex (BCC) can be life-threatening in CF patients and could constitute a contraindication for LT; however, if the infection is successfully treated prior to the surgical intervention, LT can be performed.^{46,47} BCC infection should be managed by reference centers (definition based on their long experience in the management of BCC in CF)⁴⁷: meropenem, ceftazidime, piperacillin, and trimethoprim-sulfamethoxazole show activity against BCC.^{48,49} Combination of the above-mentioned drugs can increase the treatment success rate.^{48,49}

***Nocardia* spp**

Nocardia is a well-recognized pathogen in immunocompromised hosts. Pulmonary infections in LTRs can be associated with the involvement of other organs (such as CNS).^{50,51}

Trimethoprim/sulfamethoxazole (160/800 mg per os q12h or 15 mg (based on trimethoprim)/Kg/day IV) in combination with meropenem (2g IV q8h) is the standard of care.⁵² Linezolid (600 mg IV q12 h) with meropenem (2g IV q8h) or imipenem/cilastatin (500 mg IV q6h) can represent an alternative. The duration of therapy depends on the clinical and microbiological response (up to nine months in some cases).⁵¹

Stenotrophomonas maltophilia

The diagnosis of a colonization or infection caused by *S. maltophilia* is challenging; in cases of infection, trimethoprim/sulfamethoxazole (160/800 mg orally q12h or 15 mg (based on trimethoprim)/Kg/day IV) or levofloxacin (750 mg IV daily) or minocycline (200 mg IV loading dose, then 100 mg q12h) can be administered.⁵³ Omadacycline, eravacycline, and cefiderocol are active *in vitro*, but no clinical data are available.^{54,55}

Carbapenemase-producing *Enterobacterales* (CPE) colonization and infection

Active screening with rectal swab and BAL for MDR Gram-negative bacteria should be implemented.^{31,56}

Empiric treatment with ceftazidime/avibactam (2.5g IV q8h), or meropenem-vaborbactam (4 g IV q8h), or imipenem/relebactam (1.25 g IV q6h), or ceftazidime/avibactam (2.5 g IV q8h) in association with aztreonam (2 g IV q6h), with or without aerosol and intravenous colistin, systemic fosfomycin, or aerosol and intravenous AG, can be prescribed depending on the local CPE epidemiology.^{31,57}

Cefiderocol (2 g IV q8h) can be administered in case of pan-resistant isolates.³¹

Reasoned empiric treatment of bacterial, viral and fungal infections in LT is presented in Table 1.

Viral infections

Epidemiology of viral infections post LT

Viruses represent the second cause of infection in LTRs, accounting for one third of all infections.⁵⁸ Their relevance increases with the immunosuppression peak, which can

facilitate the reactivation of latent opportunistic infections.¹ The risk decreases when immunosuppression reaches maintenance levels, although it could increase following the exposure to community-acquired respiratory viruses (CARVs),¹ which can be easily diagnosed with molecular diagnostic techniques.⁵⁹

Cytomegalovirus (CMV) is the most frequently-detected viral agent during the first month and from the second to the sixth month (75% and 80%, respectively); however, it could promote other infections, such as Epstein-Barr virus (EBV) related lymphoproliferative disorders, and acute and chronic rejection.^{60,61} CARVs account for about half of viral infections after 6 months.^{59,62}

Host predisposing factors and LT predisposing factors

The main predisposing factors for a viral infection are the significant anatomical and functional modifications caused by transplant surgery and the immunosuppression to prevent rejection. Being carrier of a viral infection (both donor and host) can be associated with a higher risk of disease although systematic screening could lower this risk.

The screening of recipients enables an assessment of the eligibility for LT and to plan vaccinations and other preventive interventions.

The highest risk of CMV infection (defined by the American Society of Transplantation as evidence of CMV replication regardless of symptoms) and disease (evidence of CMV infection with attributable symptoms) can be explained by the pulmonary lymphatic reservoir and the high level of immunosuppression.⁶³ A discordant serological status “donor-positive (D+)/recipient-negative (R-)” can be dramatic for the risk of disease.⁶⁴

EBV, which causes a latent infection in 90–95% of adults, can lead to severe and disseminated infection and to post-transplant lymphoproliferative disease when transmission occurs from a D+ to a R- (10% of LT).^{65,66} High-level immunosuppression may contribute by promoting EBV-infected B cell escape from T-cell mediated immune surveillance.⁶⁷ Several studies highlighted the association between some induction agents (e.g., OKT3), higher EBV viremia, and risk of lymphoproliferative disorders.⁶⁸

LTRs and their households should be counselled on their behaviors, including hand washing and droplet precautions, and be vaccinated against influenza annually. Reduction of immunosuppression, when possible, can help reduce the risk of severe disease.¹

Less common viral infections caused by hepatitis E virus (HEV), West Nile virus (WNV), Human T-lymphotropic virus (HTLV)-1/2, rabies, Zika virus, and lymphocytic choriomeningitis virus (LCMV) should be evaluated taking into account some important factors, such as travel and residence history, past and current employment, lifestyle, and exposure to animals.⁶⁹

Pre-LT candidate screening

LT candidates are routinely screened for the following agents: herpesviruses (HSV-1 and HSV-2, EBV, CMV, varicella zoster virus or VZV), viral hepatitis viruses (HAV, HBV, HCV), HIV, measles, mumps, and rubella (MMR).¹⁹

Table 1 Reasoned antimicrobial therapy for most common pathogens complicating lung transplantation.

Pathogen	FIRST LINE TREATMENT	ALTERNATIVE TREATMENTS
BACTERIA		
<i>S. aureus</i>	<i>If pre-LT screening negative for MRSA:</i> Cefazolin 2g IV q 8h Oxacillin 2 g IV q 4h <i>If pre-LT screening positive for MRSA:</i> Ceftaroline 600 mg IV q 8h	<i>If pre-LT screening negative for MRSA, but allergy to penicillin or cephalosporins:</i> Linezolid 600 mg IV q 12h <i>If pre-LT screening positive for MRSA:</i> Linezolid 600 mg IV q 12 h
<i>Enterococcus</i> spp.	<i>If bacteremia:</i> Ampicillin 200 mg/kg/day IV or 500 mg PO q 6 h or amoxicillin 1g PO q 8 h + ceftriaxone 2g IV q 24 h <i>If pneumonia:</i> Ampicillin 200 mg/kg/day IV or 500 mg PO q 6 h or amoxicillin 1g PO q 8 h + aminoglycosides IV/aerosol	<i>If VRE:</i> Linezolid 600 mg IV/PO q 12 h Tedizolid 200 mg PO q 24 h
<i>P. aeruginosa</i>	Ceftazidime 2g IV q 8 h or cefepime 2g IV q 8 h + aminoglycosides IV/aerosol Piperacillin/tazobactam 4.5g IV q 6h + ciprofloxacin 750 mg IV q 12 h	<i>If ESBL:</i> Meropenem 2g IV q 8 h Imipenem/cilastatin 1g IV q 6 h Ceftolozane/tazobactam 3g IV q 8h <i>If serine-carbapenemase:</i> Ceftazidime/avibactam 2.5g IV q 8h or meropenem/vaborbactam 4g IV q 8h + colistin 9 MIU IV LD then after 12h 4.5 MIU q 12h or fosfomycin 24g CI or aminoglycosides IV/aerosol <i>If metallo-carbapenemase:</i> Ceftazidime/avibactam 2.5g IV q 8h + aztreonam 2g IV q 6h Meropenem 2g IV infusion over 3h q 8h <i>If PDR:</i> Meropenem 2g IV LD then 3g CI Colistin 9 MIU IV LD then after 12 h 4.5 MIU q 12 h + colistin aerosol Meropenem/vaborbactam 4g IV q 8 h Imipenem/relebactam 1.25g IV q 6h Ceftazidime/avibactam 2.5g IV q 8h + aztreonam 2g IV q 6 h For all of the previous, evaluate the association with colistin 9 MIU IV LD then after 12 h 4.5 MIU q 12 h or fosfomycin 24g CI or aminoglycosides IV/aerosol <i>If PDR:</i> Cefiderocol 2g IV q 8 h Linezolid 600 mg IV q 12 h + meropenem 2g IV q 8h or imipenem/cilastatin 500 mg IV q 6h Levofloxacin 750 mg IV q 24 h Minocycline 200 mg IV LD then 100 mg q 12 h
<i>Acinetobacter</i> spp.	Cefepime 2g IV q 8 h (check local epidemiological data)	
CRE	Ceftazidime/avibactam 2.5g IV q 8h ± colistin 9 MIU IV LD then after 12 h 4.5 MIU q 12 h or fosfomycin 24g CI or aminoglycosides IV/aerosol (check local epidemiological data)	
<i>Nocardia</i> spp.	Trimethoprim-sulfamethoxazole 160/800 mg PO q 12 h (or 15 mg based on trimethoprim/kg/day IV) + meropenem 2g IV q 8 h	
<i>S. maltophilia</i>	Trimethoprim-sulfamethoxazole 160/800 mg PO q 12 h (or 15 mg based on trimethoprim/kg/day IV)	
<i>M. tuberculosis</i>	Based on AST. Refer to a reference center.	
<i>B. cepacia</i> complex	Refer to a reference center. Based on AST, a combination of meropenem, ceftazidime, piperacillin, trimethoprim-sulfamethoxazole should be carefully evaluated by an expert in antibiotic therapy.	
VIRUSES		

<i>Cytomegalovirus</i>	Valganciclovir 900 mg PO q 12 h Ganciclovir 0.5 mg/kg IV q 12 h	-
<i>Epstein-Barr virus</i> <i>Herpesviruses</i>	Immunosuppression reduction and other therapeutic approaches (e.g. rituximab) should be carefully evaluated by an expert in antiviral therapy. <i>Genital Herpes simplex:</i> Acyclovir 400 mg PO q 8 h for 5-10 days If severe case, acyclovir 5 mg/kg IV q 8 h for 5-7 days <i>Gingivostomatitis:</i> Acyclovir 400 mg PO q 4 h for 5 days <i>Herpes zoster (dermatomal):</i> Acyclovir 800 mg PO q 4 h for 7 days <i>Herpes zoster (disseminated):</i> Acyclovir 10 mg/kg IV q 8 h for 7–14 days <i>Acute varicella:</i> Acyclovir 10–12 mg/kg IV q 8 h for 7 days <i>Encephalitis:</i> Acyclovir 10–12.5 mg/kg IV q 8h for 14–21 days	<i>Genital Herpes simplex:</i> Famciclovir 500 mg PO q 12 h for 5-10 days Valacyclovir 1g PO q 12 h for 5–10 days <i>Gingivostomatitis:</i> Famciclovir 500 mg PO q 12 h for 7 days Valacyclovir 2g PO q 12 h for 1 day <i>Herpes zoster (dermatomal):</i> Valacyclovir 1g PO q 8 h for 7 days
<i>Influenza virus</i> <i>Parainfluenza virus</i>	Oseltamivir 75 mg PO q 12h Ribavirin IV. Day1: 600 mg LD then 200 mg q 8 h; day 2: 400 mg q 8 h; day 3 forward: increase up to 10 mg/kg q 8 h. Evaluate switch to ribavirin PO.	Zanamivir 10 mg aerosol q 12 h Ribavirin aerosol (discouraged for potential toxicity and high cost)
<i>Respiratory syncytial virus</i>	Ribavirin IV. Day1: 600 mg LD then 200 mg q 8h; day 2: 400 mg q 8 h; day 3 forward: increase up to 10 mg/kg q 8 h. Evaluate switch to ribavirin PO.	Ribavirin aerosol (discouraged for potential toxicity and high cost)
Fungi <i>Aspergillus</i> spp.	Voriconazole: weight-based dosing IV/PO (target levels 1–5.5 µg/mL)	Isavuconazole 200 mg q IV / PO 8 h for 6 doses, then 200 mg q 24 h
<i>Candida</i> spp.	Caspofungin 70 mg LD then 50 mg IV q 24 h When the patient is stable, consider early transition to oral therapy with triazole (e.g. fluconazole)	Micafungin 100 mg IV q 24 h Anidulafungin 200 mg LD then 100 mg IV q 24 h
<i>Cryptococcus</i> spp.	Fluconazole 400 mg PO q 24h for 6-12 months. <i>Meningoencephalitis:</i> Liposomal AmB 3-4 mg/kg IV q 24 h for 2 weeks + fluconazole 400–800 mg IV/PO q 24 h for 8 weeks + fluconazole 200–400 mg IV/ PO q 24 h for 6–12 months	-
<i>P. jirovecii</i>	Trimethoprim-sulfamethoxazole 15–20 mg/kg of the TMP component IV divided in 3–4 doses for at least 14 days.	Alternative agents (pentamidine, atovaquone, primaquine, clindamycin) are much less effective than TMP-SMX.

Dosages refer to adult patients with normal renal function.

LT: lung transplantation; MDR: multidrug-resistant; PDR: pandrug-resistant; AST: antimicrobial susceptibility testing; MRSA: methicillin-resistant *S. aureus*; VRE: vancomycin-resistant *Enterococcus*; CRE: carbapenemase-producing *Enterobacterales*; IV: intravenous; PO: per os; CI continuous infusion; LD: loading dose; MIU: millions international units; AmB: amphotericin B; ABLC: amphotericin B lipid complex; TMP-SMX: Trimethoprim-sulfamethoxazole.

In cases of acute disease, transplantation is usually postponed.⁷⁰

CMV-specific IgG test shows high sensitivity and specificity; in the case of negativity, a second test should be performed immediately before transplant; uncertain results should be considered positive and the patient at high risk.⁷¹

The incidental diagnosis of a chronic viral infection (e.g., HIV, HCV, HBV) can lead to a reassessment of LT feasibility and timing.^{72–76}

Serology related to vaccine-preventable diseases (e.g., HAV and HBV, MMR, and VZV) is mandatory to plan an immunization program before LT, mainly for live attenuated vaccines (e.g., MMR and VZV vaccines).⁷⁷

Pre-LT donor screening

Donor serological status for HIV, HBV, HCV, CMV, EBV, and WNV should be carefully evaluated when the lung explant is scheduled (and not >28 days before) and matched with the serostatus of the recipient.^{19,78}

Nucleic acid amplification testing (NAT) is recommended routinely for HCV, HIV, and HBV (in case of highest risk).^{19,78,79}

In deceased donors, NAT for HIV, HCV, and HBV is recommended and results, if not available before transplant, can be used to prescribe the recipient's treatment.^{78,79}

HIV-1/2 screening with fourth-generation test (or alternatively, third-generation combined with NAT) is recommended.

HBV infection should be screened evaluating HBsAg, HBcAb IgM and IgG, whereas NAT is recommended in deceased donors and those deemed at highest risk.^{19,78} Transplant is contraindicated when the donor is HBsAg and/or HBcAb IgM positive and recipient is HbsAb negative; if the recipient is HBsAb positive, a life-saving transplant associated with pre-emptive therapy should be considered.¹⁹ In cases of transplant from donors with only HBcAb IgG, the serological recipient profile should be carefully considered and different preventive approaches should be adopted: prophylaxis with HBIG and antivirals in the case of positive HBsAb or positive HBsAb and negative HBcAb, no prophylaxis in case of positive HBsAb and HBcAb.¹⁹

Three donor types can be identified after HCV screening: uninfected donors (HCVAb/NAT negative); donors with cleared infection (HCVAb positive/NAT negative), considered similar to uninfected donors^{80,81}; actively infected donors (HCVAb/NAT positive), which should be taken into consideration when highly active antiviral therapies are available.^{82–84}

Assessment of CMV and EBV serostatus (CMV IgG and viral capsid antigen VCA-IgG, respectively) of donor and recipient is key to define pre-transplant prevention planning, as well as the risk of post-transplant EBV-associated lymphoproliferative diseases (PTLD).^{71,85} The “D+/R-” status is at higher risk of severe infection.¹⁹

In the case of CMV-specific IgG negativity at the first evaluation, a second test should be performed immediately before transplant; uncertain results should be considered as positive and the combination “donor–recipient” at the highest risk.⁷¹

Focused screening of less incident viruses should be addressed based on clinical and epidemiological data.^{19,69,86}

Post-LT monitoring and prevention

The risk of life-threatening post-LT disease and the opportunity for prevention and/or early treatment justify post-LT systematic monitoring for CMV and EBV.

Cytomegalovirus

Monitoring of CMV DNAemia by quantitative nucleic acid amplification testing (qNAT), in LTRs is the gold standard for a prompt diagnosis of CMV infection and disease.^{71,87} Whole blood positivity is helpful for an early assessment of the infection, whereas plasmatic persistence of DNAemia is a predictor of treatment failure.⁸⁸ Both whole blood and plasma can be used but the same specimen should be used during the monitoring process.⁷¹ Antigenemia testing (pp65) in peripheral white blood cells is an alternative option, but it is labor-intensive and less accurate.⁸⁹

CMV prevention strategies are based on two approaches: “universal prophylaxis” and “preemptive therapy”.

Universal prophylaxis depends on the immediate administration (within 10 days after LT) of a preventive dose of antivirals in at-risk LTRs for a definite period of time. Based on the high rates of CMV infection (R negative) and reactivation (R positive) this approach is strongly recommended.⁷¹

Intravenous ganciclovir 5 mg/kg once daily is the drug of choice and can be switched to oral valganciclovir 900 mg once daily when oral administration is feasible; both drugs need dose adjustment in cases of renal dysfunction.⁷¹

A therapy duration of 6–12 months is recommended: 12 months in D+/R-, whereas at least 6 months in D+/R+ and D-/R+. ^{71,90} Prophylaxis is not routinely recommended in D-/R-; thus, prophylaxis of herpes virus and varicella (acyclovir, valganciclovir or famciclovir) should be evaluated.⁷¹

Preemptive therapy is based on the regular monitoring of CMV replication (e.g., weekly) for 3–4 months after LT, in order to promptly prescribe treatment to prevent the disease. Longer intervals of screening are associated with an increased incidence of disease and shorter survival.^{71,91} Once a critical threshold (not universally established) is achieved, valganciclovir should be started. Currently, preemptive therapy is not recommended in LT because of the high risk of CMV disease and the limits of screening standardization.^{71,92}

The occurrence of post-prophylaxis (or late-onset) CMV disease, possibly associated with a reduced cell-mediated immunity, is frequently observed in cases of LT, high-dose immunosuppression, universal prophylaxis ≤ 6 months and D+/R- serostatus.^{71,90,93} Weekly surveillance after prophylaxis for 8–12 weeks should be considered.⁷¹

Epstein-Barr virus

EBV seronegative recipients are at high risk of primary infection and PTLD (highest incidence within 1 year from transplant)⁹⁴; thus, EBV-DNA monitoring and early treatment should be considered. Prophylaxis or pre-emptive strategies with acyclovir or ganciclovir are supported by poor data.⁹⁵ Blood EBV-DNA should be monitored monthly for 6 months, followed by an assessment every 3 months until 12 months post LT.⁸⁶

Other herpesviruses

The high prevalence of HSV-1/2 and VZV latent infection both in donors and recipients and the availability of effective prophylaxes and VZV vaccination make those infections of minor concern. Furthermore, anti-CMV agents can prevent other Herpesvirus infections. In the case of a CMV preemptive strategy and seronegative recipients, prophylaxis with acyclovir 400–800 mg po every 12 h (alternatively, valganciclovir 500 mg po every 8–12 h or famciclovir 250 mg po every 12 h) is recommended during the first month after transplant and during periods of intensified immunosuppression.⁹⁶ In cases of exposure to a patient with varicella and a recipient seronegative status, prophylaxis with acyclovir or valganciclovir is recommended and Varicella-zoster immunoglobulins (VZIG) (125 units/10 kg IM, minimum dose of 125 units, maximum of 625 units) should be administered within 96 h (up to 10 days).^{97–99}

Pre-LT screening for HHV8 (also known as Kaposi's sarcoma-associated herpesvirus -KSHV) is recommended^{100,101}; in cases of HHV8 D+/R- transplant close monitoring of HHV8-DNA in the blood is recommended.⁸⁶

Community-acquired respiratory viruses

CARVs includes human rhinovirus, influenza, parainfluenza, adenovirus, respiratory syncytial virus (RSV), and coronavirus (CoVs), which can cause lower respiratory

tract infections, acute and chronic rejection, and death.^{102,103}

Prevention is based on hand hygiene and precautions against transmission of droplets; accurate diagnostics (PCR-based testing on nasopharyngeal swab, bronchial aspirate, or BAL) are key for early diagnosis.

Currently, immunization is available against influenza, RSV and SARS-CoV-2.

Pre-exposure prophylaxis should be considered during the influenza season or when vaccination is contraindicated or expected to confer low protection (e.g., high-level immunosuppression).¹⁰⁴ Post-exposure prophylaxis with oral oseltamivir or inhaled zanamivir (75 mg po and 10 mg respectively, once daily, respectively) should be administered to unvaccinated LTRs within 48 h of contact and for 5–10 days afterwards.¹ Oseltamivir is recommended over zanamivir in the U.S. for the treatment of influenza. In the countries where it is available, zanamivir represents an alternative to oseltamivir and it is recommended for the treatment of uncomplicated influenza A and/or B in patients aged 7 years and older with symptoms for no more than 2 days. Of note, Zanamivir should not be administered in intubated patients. In LTRs under prophylaxis who develop flu-related symptoms, prompt testing and initiation of therapy treatment is recommended.¹⁰⁴

Fig. 3 summarizes the main characteristics of viral infections in LT.




Fig. 3 Viral infections in LT. In the first six months after LT, CMV infection and disease is the most frequent viral infection, followed by EBV disseminated primary infection and EBV-related lymphoproliferative disorders. Based on individual risk factors, viral hepatitis, HIV, West Nile virus, HTLV-1/2, rabies virus, Zika virus, LCMV and HHV8 infections should be investigated. In the late post-LT period, community-acquired respiratory viruses represent the main risk. Risk factors and suggestions on how to prevent viral infections are shown in the red box. (Source: authors elaboration).

Antiviral therapy in LT

Cytomegalovirus

Oral valganciclovir (900 mg every 12 h) and intravenous ganciclovir (0.5 mg/kg every 12 h) are the first-line drugs in cases of mild-to-moderate and severe-to-life-threatening disease, respectively. Ganciclovir is recommended in cases of gastrointestinal CMV disease or in cases of reduced bioavailability.⁷¹

Blood counts and renal parameters should be strictly monitored to assess their toxicity.

DNAemia should be monitored weekly; treatment should last ≥ 2 weeks up to clinical recovery and DNAemia eradication (a single negative determination with a highly sensitive test, or two consecutive negative results with a less sensitive test).^{71,105}

In the case of treatment failure (persistent high DNAemia or its increase during treatment), the most prevalent resistance mutations (UL97 and UL54) should be evaluated in order to perform a therapeutic switch to second-line antivirals (foscarnet, cidofovir).^{106,107}

Secondary prophylaxis is not associated with fewer relapses and is not routinely recommended.^{108,109}

Epstein-Barr virus

A significant increase in EBV-DNA (e.g., $>10^3$ IU/mL) should be rapidly investigated and may require a prompt reduction of the immunosuppression level, as well as the prescription of other therapeutic approaches (e.g., rituximab).⁸⁶

Other herpesviruses

Treatment of HSV1-1/2 and VZV infection depends on their clinical manifestations^{97,110} (Table 1).

Community-acquired respiratory viruses (CARVs)

Treatment of influenza should be started ideally within 48 h following the onset of symptoms, but may be beneficial up to 5 days afterward; 10 or more days should be considered according to severity and immunosuppression and dose adjustment based on renal function is recommended^{104,110} (Table 1). Treatment of RSV and *Parainfluenza virus* are reported in Table 1.¹¹¹⁻¹¹³

LT and SARS-CoV-2 infection (COVID-19)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is an emerging pathogen isolated for the first time in December 2019 in Wuhan, China.¹¹⁴ Due to its airborne transmission and high contagiousness, it resulted in a pandemic, officially declared by WHO in March 2020.¹¹⁵ The International Society of Heart and Lung Transplantation (ISHLT) promptly released guidelines that have recently been updated.¹¹⁶

Host predisposing factors and LT predisposing factors

Several retrospective cohort studies reported controversial results regarding the outcome of LT recipients affected by COVID-19.¹¹⁷⁻¹²² LTRs should be cautiously considered at high risk of developing COVID-19.^{116,123}

The risk of disease decreases when medical facility visits are reduced and social interactions minimized.¹¹⁶

Pre-LT candidate screening

The risk of exposure should be evaluated in LT candidates and a PCR test for SARS-CoV-2 should be performed. Candidates may be considered suitable for LT if:

- Asymptomatic with a negative PCR test.
- Symptomatic with a negative PCR test and an alternative diagnosis which does not contraindicate LT.
- Exposed but asymptomatic >7 days after exposure with two negative PCR tests performed 24–48 h apart, and at high risk of death without organ transplantation.
- Previously symptomatic, following clinical resolution and at least 14 days from the onset of symptoms, with two negative PCR tests performed 24–48 h apart, and without COVID-19 related organ damage, at high risk of death without organ transplantation.
- Asymptomatic with positive PCR test, at least 14 days after diagnosis with two negative PCR tests at least 24–48 h apart.

Pre-LT donor screening

LT donors should be screened to assess the exposure risk and should undergo a PCR test for SARS-CoV-2 <72 h before organ explant.¹¹⁶ Their organ may be considered suitable for LT if:

- Asymptomatic with a negative PCR test.
- Symptomatic with a negative PCR test and an alternative diagnosis which does not contraindicate organ donation.
- Exposed but asymptomatic >7 days after exposure with two negative PCR tests performed 24–48 h apart (at least one a respiratory sample of the lower airways), without COVID-19 pulmonary involvement and negative CT, with a recipient candidate showing to be at high risk of death without LT.
- Previously symptomatic, following clinical resolution and at least 28 days from the onset of symptoms, with two negative PCR tests performed 24–48 h apart (including a respiratory sample of the lower airways), negative chest CT, and no other COVID-19 related organ damage.

Post-LT monitoring and prevention

LTRs should be monitored in accordance with international guidelines and local policies.

Antiviral therapies and open issues on COVID-19 and LT

To date, no consensus guidelines on treatment of COVID-19 in SOT recipients have been issued. DDIs and cardiac and pulmonary diseases represent the major concerns. Prescription of protease inhibitors (lopinavir/ritonavir, darunavir/ritonavir and darunavir/cobicistat) and chloroquine/hydroxychloroquine has been discouraged due to the lack of evidence and the high risk of DDIs and adverse events (e.g., QTc prolongation).¹²⁴⁻¹²⁸ Preliminary data on remdesivir suggest a low risk of significant DDIs.¹¹⁶

The inclusion of SOT recipients in COVID-19 clinical trials is urgently needed.

Parasitic infections

While parasitic infections are rarely reported in LTR, careful assessment of pre-transplant risk factors of the LTR and the donor (epidemiology, possible exposure, travel history, previous immunosuppressive treatments) needs to be carried out.^{129–131}

Trypanosoma cruzi and *Strongyloides* spp. may cause disseminated disease in immunocompromised patients, with high morbidity and mortality.^{132–134}

Fungal infections

Epidemiology of fungal infections post LT

According to the Transplant Associated Infection Surveillance Network (TRANSNET), 8.6% of LTRs develop invasive fungal infections during the first year after LT,¹³⁵ although the incidence can vary based on various relevant clinical and epidemiological drivers (e.g., patient population, immunosuppressive drugs, antifungals and antibiotic prophylaxis).¹³⁶ Fungal pneumonia contributes to 35% of pneumonia-related deaths during the first year after LT.¹³⁷

The most frequent fungal pathogens are *Aspergillus* spp. (44%; mainly *Aspergillus fumigatus*), *Candida* spp. (23%; mainly *Candida albicans*), *Scedosporium* spp. and *Fusarium*

spp. (20%).^{136,137} The incidence of *Pneumocystis jirovecii* pneumonia (PJP) has decreased owing to effective prophylaxis, whereas other molds (e.g., *Cryptococcus neoformans*, *Mucor*, *Rhizopus*) account for a reduced proportion of cases.

The host predisposing factors and LT predisposing factors

Several host and environmental factors can increase the risk of invasive fungal infection (IFI) following LT. In particular, anatomic and physiologic impairment and environmental exposure (e.g., farming and construction, sandblasting, air conditioning filters, flooded sites) increase the risk of IFI.

Airway ischemia, neutropenia, hypogammaglobulinemia, T-cell depletion and an over-immunosuppressed state, the need for bronchial stents, co-infection with CMV disease, and previous colonization with *Aspergillus* are all risk factors for IFI.¹³⁸ Patients with cystic fibrosis are often colonized with fungi, while receiving a single-lung transplant poses a higher risk of invasive fungal infection compared with double-lung transplant recipients.

Fig. 4 summarizes the main characteristics of fungal and parasitic infections complicating LT.

LTR screening

Correct identification of patients at increased risk of fungal infection is key to IFI prevention.




Fig. 4 Fungal and parasitic infections in LT. Invasive fungal infections in LTRs mainly occur within 12 months after LT. *Aspergillus* spp. and *Candida* spp. are the most frequent fungi responsible for infections in this setting. Asking for environmental and occupational exposure is fundamental to raise suspicion on high-risk patients. Based on individual risk factors, galactomannan and 1,3-β-D-glucan should be investigated. Parasitic infections in LTRs rarely occur, but the local epidemiology and personal travel history should always be kept in mind. (Source: authors elaboration).

LTRs have a significant risk of IFI caused mainly by *Candida spp.* and *Aspergillus spp.* A definitive diagnosis of IFI (such as invasive aspergillosis, and invasive candidiasis) requires histological evidence for infection or positive culture.¹³⁹ Nevertheless, the use of nonculture diagnostic tests facilitates the detection of IFI.²⁹

According to the European Society of Clinical Microbiology and Infectious Diseases (ESCMID),¹³⁹ mannan and anti-mannan detection enable the identification of *Candida spp.* in serum samples, whereas serum 1,3- β -D-glucan testing is often used as a first-stage screening test, as it is present in large amounts of fungal species.^{139,140} The application of galactomannan assay to BAL fluid coupled with serum galactomannan and serum 1,3- β -D-glucan expedites the diagnosis of invasive pulmonary aspergillosis in organ transplant recipients.¹⁴¹

Immunofluorescence microscopy and real-time PCR techniques on BAL are the recommended methods for PJP diagnosis; serum 1,3- β -D-glucan has a high negative predictive value in HIV patients, while increased levels can only support diagnosis.¹⁴²

Prophylaxis in LTRs

Minimization of environmental exposures and the use of personal protective equipment can reduce the risk of colonization and infection.¹³⁸

A preemptive therapy can be administered. Nevertheless, no consensus on the antifungal agent, route of administration, and duration of prophylaxis has been reached.¹³⁶

Inhaled amphotericin B is commonly used, as it is active against the most prevalent fungi. Optimal dosage, formulation, and duration are not standardized.¹³⁹

Triazoles are commonly used for antifungal prophylaxis and voriconazole is the most frequently administered,^{29,138,139} followed by itraconazole¹⁴³ and posaconazole.¹⁴⁴ In particular, posaconazole appears effective in the management of IFI after LT, and well-tolerated. It could be considered if the use of traditional antifungal treatments is limited by drug resistance, drug interactions, and toxicities.¹⁴⁴

Isavuconazole has been identified as non-inferior to voriconazole in invasive mold infections caused by *Aspergillus* and other filamentous fungi.^{145,146} Isavuconazole appears to be active against all *Candida* species and the most common *Aspergillus* species.¹⁴⁷ Nevertheless, an increased incidence of IFI in neutropenic hematologic malignancy patients and hematopoietic cell transplant recipients during isavuconazole prophylaxis has been observed.¹⁴⁸ This suggests the need for additional studies to determine the role of isavuconazole as prophylaxis in such patients.

Echinocandins show activity against *Candida spp.*, *Aspergillus spp.*, and other molds. However, they are not active against *Cryptococcus spp.*, *Histoplasma capsulatum*, *Coccidioides immitis*.

LT is burdened with the higher risk of PJP among SOT recipients. Prophylaxis is recommended for a minimum of 6–12 months (in the case of standard risk) to lifelong (reserved for high risk).¹⁴⁹ Trimethoprim–sulfamethoxazole (TMP–SMX) 160 mg/800 mg orally daily or three times weekly is the drug of choice, while dapsone (50–100 mg po daily), atovaquone (1500 mg po daily) and aerosolized

pentamidine (300 mg q 3–4 wk) are alternative agents in the case of TMP–SMX intolerance.¹⁵⁰ The emerging occurrence of late onset PJP after 12-month prophylaxis supports the usefulness of an as-long-as-possible prophylaxis in LTRs.¹⁵¹

Treatment

Aspergillus

Voriconazole is the drug of choice for the treatment of invasive aspergillosis.^{29,139,149,152} Weight-based dosing is recommended to achieve optimal therapeutic ranges, with incremental increases and monitoring (i.e., 50% increase in daily dose) for those with trough levels <1 μ g/mL. Target levels should range from >1 to <5.5 μ g/mL (Table 1). Voriconazole can increase the levels of some immunosuppressants (i.e., tacrolimus, cyclosporine, and sirolimus), and its serum through concentration is monitored 5–7 days into the therapy.

Among triazoles, isavuconazole is a broad-spectrum antifungal agent for the treatment of invasive aspergillosis (200 mg q 8 h for 6 doses, then 200 mg daily).^{144–146} Even though isavuconazole and posaconazole show fewer DDIs than voriconazole, posaconazole retain DDI with tacrolimus and serum concentrations of both drugs should be carefully monitored.^{144,145}

Candida

Candida infection usually manifests as candidemia and invasive candidiasis following LT. Based on the guidelines published by the American Society of Transplantation Infectious Diseases Community of Practice, the treatment in LTRs is similar to the one prescribed to other patient populations.¹⁵³

An echinocandin is initially recommended (caspofungin, loading dose 70 mg, then 50 mg IV daily; micafungin, 100 mg IV daily; anidulafungin, 200 mg loading dose, then 100 mg IV daily). When patients are stable and the organism is susceptible, early transition to oral therapy with triazole (e.g. fluconazole) is recommended (Table 1).

Cryptococcus

Cryptococcosis is the third most common invasive fungal infection in SOT recipients. No randomized controlled trials of antifungal therapy for cryptococcosis in SOT recipients have been performed, and treatment recommendations result from the cohorts of HIV-infected patients. According to the Infectious Diseases Society of America, the drug of choice for nonmeningeal cryptococcosis is fluconazole 400 mg per day for 6–12 months (Table 1).¹⁵⁴

Treatment recommendations for cryptococcal meningoencephalitis in LTR consist of: i) 2 weeks of induction therapy, liposomal AmB (3–4 mg/kg per day) or amphotericin B lipid complex (ABLC) (5 mg/kg per day) plus flucytosine (100 mg/kg per day); 8 weeks of consolidation therapy, fluconazole (400–800 mg per day); 6 months to 1-year of maintenance therapy, fluconazole (200–400 mg per day).

Pneumocystis jirovecii pneumonia

Trimethoprim–sulfamethoxazole (TMP–SMX) represents the first-line agent and the drug of choice for the treatment of PJP in LTRs (adults: 15–20 mg/kg/day of the TMP

component, IV q 6–8 h; children >2 months: 3.75–5 mg/kg/dose of the TMP component and 19–25 mg/kg/dose of the SMX component given IV q 6 h).¹⁴⁹ The length of treatment is at least 14 days, and corticosteroids should be associated when pAO₂ < 70 mm Hg (adults: 40–60 mg of prednisone equivalent po/iv bid–tid with tapering after one week over a period of 7–14 days; children: 1 mg/kg po bid for 5 days, then 0.5 mg/kg po bid for 5 days, then 0.5 mg/kg po qd for 10 days).¹⁴⁹ Second-choice drugs include alternative agents that are less effective than TMP-SMX and include iv pentamidine, atovaquone, primaquine and clindamycin (Table 1).¹⁴⁹

Limitation of the study and conclusion

The major limitation of the present article lies in the narrative nature of the review compared to those performed systematically. However, the aim of the present study was to provide a concise summary on infectious diseases in lung transplanted patients to guide clinicians dealing with daily issues related to infectious diseases in the immunocompromised hosts. Furthermore, it would be ideal to produce a living document, which is possible for some international guidelines, to update the scientific evidence on the basis of new valuable studies. We could not grade the quality of the evidence and, then, the recommendations, which is usually performed when systematic reviews are carried out. However, the systematic reviews do address specific aims and do not cover a broad range of topics as we did.

In fact, prompt and comprehensive assessment of pre-transplantation infectious comorbidities, both in LT recipient and living donors, from rectal swabs for MDR-colonization to viral serology, and potentially parasitic infections, is needed to decrease the risk of infections and increase the likelihood of patients' survival. Furthermore, careful assessment of anti-viral and anti-fungal prophylaxis, as well as reasoned empiric antimicrobial treatment, should be tailored on patient's risk factors, microbial colonization, and type of post-transplant immune-suppression.^{71,116,138}

Funding

None. The study is part of the IFALT Working group Activities.

Conflicts of interest

None to declare.

Acknowledgments

We acknowledge the scientific contribution and support of the IFALT working group. Internal Medicine Department, Division of Infectious Diseases, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano (Milano, Italy): Laura Alagna, Marina Allegrini, Alessandra Bandera, Matteo Bolis, Manuela Carugati, Valentina Ferroni, Andrea Gori, Teresa Itri, Davide Mangioni, Debora Mondatore, Valeria Pastore, and Federica Portunato. Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center,

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano (Milano, Italy): Stefano Aliberti, Francesco Blasi, Letizia Corinna Morlacchi, Martina Oriano, Valeria Rossetti, Paolo Tarsia, and Leonardo Terranova. Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano (Milano, Italy): Rosaria Carrinola, Francesco Damarco, Paolo Mendogni, Mario Nosotti. Alessandro Palleschi, Ilaria Righi, Lorenzo Rosso, and Davide Tosi. Pathology Department, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano (Milano, Italy): Stefano Bogetto Ferrero. Department of Biomedical and Clinical Sciences, Università degli Studi di Milano (Milano, Italy): Mario Clerici, Claudio Fenizia, and Daria Trabattoni. Department of Oncology and Hemato-Oncology, Università degli Studi di Milano (Milano, Italy): Claudia Alteri and Carlo Federico Perno. Genprobio srl: Marco Ventura and Claudio Pessina. Prossima Isola srl: Daniele Idini.

The authors would like to thank Emma Dempsey for the English language revision.

References

1. Sims KD, Blumberg EA. Common infections in the lung transplant recipient. *Clin Chest Med*. 2011;32(2):327–41.
2. Remund KF, Best M, Egan JJ. Infections relevant to lung transplantation. *Proc Am Thorac Soc*. 2009;6(1):94–100.
3. Bonvillain RW, Valentine VG, Lombard G, LaPlace S, Dhillon G, Wang G. Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation. *J Hear Lung Transplant*. 2007;26(9):890–7.
4. Hayanga JWA D, Cunha J. The surgical technique of bilateral sequential lung transplantation. *J Thorac Dis*. 2014;6(8):1063–9.
5. Speich R, van der Bij W. Epidemiology and management of infections after lung transplantation. *Clin Infect Dis*. 2001;33(Suppl 1):S58–65.
6. Avery RK. Infections after lung transplantation. *Semin Respir Crit Care Med*. 2006;27:544–51.
7. Yüsen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, et al. The registry of the international society for heart and lung transplantation: thirty-first adult lung and heart-lung transplant report - 2014; Focus theme: retransplantation. *Proc J Heart Lung Transpl*. 2014;33(10):1009–24.
8. Boussaud V, Guillemain R, Grenet D, Coley N, Souilamas R, Bonnette P, Stern M. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with *Burkholderia cepacia* complex: results from two French centres. *Thorax*. 2008;63(8):732–7. <https://doi.org/10.1136/thx.2007.089458>.
9. Dudau D, Camous J, Marchand S, Pilorge C, Rézaiquia-Delclaux S, Libert JM, et al. Incidence of nosocomial pneumonia and risk of recurrence after antimicrobial therapy in critically ill lung and heart-lung transplant patients. *Clin Transplant*. 2014;28(1):27–36. <https://doi.org/10.1111/ctr.12270>.
10. Palacio F, Reyes LF, Levine DJ, Sanchez JF, Angel LF, Fernandez JF, et al. Understanding the concept of health care-associated pneumonia in lung transplant recipients. *Chest*. 2015;148(2):516–22. <https://doi.org/10.1378/chest.14-1948>.
11. Mortensen E, Hellinger W, Keller C, Cowan LS, Shaw T, Hwang S, et al. Three cases of donor-derived pulmonary tuberculosis in lung transplant recipients and review of 12 previously reported cases: opportunities for early diagnosis and prevention. *Transpl Infect Dis*. 2014;16(1):67–75. <https://doi.org/10.1111/tid.12171>.

12. Huang HC, Weigt SS, Derhovanessian A, Palchevskiy V, Ardehali A, Sagar R, et al. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. *J Hear Lung Transplant*. 2011;30(7):790–8. <https://doi.org/10.1016/j.healun.2011.02.007>.
13. Longworth SA, Vinnard C, Lee I, Sims KD, Barton TD, Blumberg EA. Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study. *Transpl Infect Dis*. 2014;16(1):76–83. <https://doi.org/10.1111/tid.12170>.
14. Lee JT, Hertz MI, Dunitz JM, Kelly RF, D'Cunha J, Whitson BA, et al. The rise of *Clostridium difficile* infection in lung transplant recipients in the modern era. *Clin Transplant*. 2013;27(2):303–10. <https://doi.org/10.1111/ctr.12064>.
15. Len O, Rodríguez-Pardo D, Gavalda J, Aguado JM, Blanes M, Borrell N, et al. Outcome of *Clostridium difficile*-associated disease in solid organ transplant recipients: a prospective and multicentre cohort study. *Transpl Int*. 2012;25(12):1275–81. <https://doi.org/10.1111/j.1432-2277.2012.01568.x>.
16. Trifan A, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, et al. Proton pump inhibitors therapy and risk of *Clostridium difficile* infection: systematic review and meta-analysis. *World J Gastroenterol*. 2017;23(35):6500–15.
17. Okamoto K, Santos CAQ. Management and prophylaxis of bacterial and mycobacterial infections among lung transplant recipients. *Ann Transl Med*. 2020;8(6):413.
18. Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. *Am J Respir Crit Care Med*. 1999;160(5 Pt 1):1611–6.
19. Malinis M, Boucher HW. Screening of donor and candidate prior to solid organ transplantation—Guidelines from the American society of transplantation infectious diseases community of practice. *Clin Transplant*. 2019;33(9).
20. Ramos KJ, Smith PJ, McKone EF, Pilewski JM, Lucy A, Hempstead SE, et al. Lung transplant referral for individuals with cystic fibrosis: cystic fibrosis foundation consensus guidelines. *J Cyst Fibros*. 2019;18(3):321–33.
21. Morris MI, Daly JS, Blumberg E, Kumar D, Sester M, Schluger N, et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. *Proc Am J Transpl*. 2012;12(9):2288–300.
22. Mattner F, Fischer S, Weissbrodt H, Chaberny IF, Sohr D, Gottlieb J, et al. Post-operative nosocomial infections after lung and heart transplantation. *J Hear Lung Transplant*. 2007;26(3):241–9.
23. Abbo LM, Grossi PA. Surgical site infections: guidelines from the American society of transplantation infectious diseases community of practice. *Clin Transplant*. 2019;33(9):e13589.
24. Kramer MR, Stoehr C, Lewiston NJ, Starnes VA, Theodore J. Trimethoprim-sulfamethoxazole prophylaxis for pneumocystis carinii infections in heart-lung and lung transplantation—how effective and for how long? *Transplantation*. 1992;53(3):586–9.
25. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Surg Infect (Larchmt)*. 2013;14(1):73–156.
26. De Bruyn G, Whelan TP, Mulligan MS, Raghu G, Limaye AP. Invasive pneumococcal infections in adult lung transplant recipients. *Am J Transplant*. 2004;4(8):1366–71.
27. Bassetti M, Poulakou G, Kollef MH. The most recent concepts for the management of bacterial and fungal infections in ICU. *Intensive Care Med*. 2018;44(11):2000–3.
28. Timsit JF, Lipman J, Bassetti M. Antimicrobial de-escalation is part of appropriate antibiotic usage in ICU. *Intensive Care Med*. 2020;46(5):1039–42.
29. Shoham S, Shah PD. Impact of multidrug-resistant organisms on patients considered for lung transplantation. *Infect Dis Clin N Am*. 2013;27(2):343–58.
30. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. *Am J Respir Crit Care Med*. 2009;180(9):802–8.
31. Bassetti M, Peghin M, Vena A, Giacobbe DR. Treatment of infections due to MDR gram-negative bacteria. *Front Med (Lausanne)*. 2019;6:74.
32. Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. *Lancet Infect Dis*. 2020;21(2):226–40.
33. Goncalves-Pereira J, Silva NE, Mateus A, Pinho C, Pova P. Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients. *BMC Pharmacol Toxicol*. 2014;15:21.
34. Del Bono V, Giacobbe DR, Marchese A, Parisini A, Fucile C, Coppo E, et al. Meropenem for treating KPC-producing *Klebsiella pneumoniae* bloodstream infections: should we get to the PK/PD root of the paradox? *Virulence*. 2017;8(1):66–73.
35. Shambat SM, Chen P, Hoang ATN, Bergsten H, Vandenesch F, Siemens N, et al. Modelling staphylococcal pneumonia in a human 3D lung tissue model system delineates toxin-mediated pathology. *DMM Dis Model Mech*. 2015;8(11):1413–25.
36. St-Pierre J, Poirier C, Chalaoui J, Ferraro P, Martel-Laferrière V, Koh G, et al. Association between pre-transplant *Staphylococcus aureus* colonisation and post-transplant *S. aureus* infection among cystic fibrosis lung transplant recipients. *Open Forum Infect Dis*. 2014;1:S163.
37. Clark SB, Hicks MA. *Staphylococcal Pneumonia*. Treasure Island (FL): StatPearls Publishing; 2021. [Updated 2020 Oct 1] Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559152/>.
38. Self WH, Wunderink RG, Williams DJ, Zhu Y, Anderson EJ, Balk RA, et al. *Staphylococcus aureus* community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. *Clin Infect Dis*. 2016;63(3):300–9.
39. Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The clinical utility of methicillin-resistant *Staphylococcus aureus* (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications. *Clin Infect Dis*. 2018;67(1):1–7.
40. Riccardi N, Monticelli J, Antonello RM, Di Lallo G, Frezza D, Luzzati R, et al. Therapeutic options for infections due to vanB genotype vancomycin-resistant enterococci. *Microb Drug Resist*. 2020;27(4):536–45.
41. Bucheli E, Kralidis G, Boggian K, Cusini A, Garzoni C, Manuel O, et al. Impact of enterococcal colonization and infection in solid organ transplantation recipients from the Swiss Transplant Cohort Study. *Transpl Infect Dis*. 2014;16(1):26–36.
42. Riccardi N, Alagna R, Sadari L, Ferrarese M, Castellotti P, Mazza E, et al. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres. *BMC Infect Dis*. 2019;19(1):564.
43. Riccardi N, Villa S, Alagna R, Giacomelli A, Sadari L, Cirillo DM, et al. Advantages and challenges of tailored regimens for drug-resistant tuberculosis: a stopTB italia look into the future. *Infect Drug Resist*. 2020;13:2795–800.
44. Shitrit D, Bendayan D, Saute M, Kramer MR. Multidrug resistant tuberculosis following lung transplantation: treatment with pulmonary resection. *Thorax*. 2004;59(1):79–80.
45. Winthrop KL, Kubak BM, Pegues DA, Hufana C, Costamagna P, Desmond E, et al. Transmission of *Mycobacterium tuberculosis* via lung transplantation. *Am J Transplant*. 2004;4(9):1529–33.
46. Olland A, Falcoz PE, Kessler R, Massard G. Should cystic fibrosis patients infected with *Burkholderia cepacia* complex be listed

- for lung transplantation? *Interact Cardiovasc Thorac Surg*. 2011;13(6):631–4.
47. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014 - An update from the pulmonary transplantation council of the international society for heart and lung transplantation. *J Hear Lung Transplant*. 2015;34:1–15.
 48. Horsley A, Jones AM, Lord R. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. *Cochr Database Syst Rev*. 2016.
 49. Semler DD, Goudie AD, Finlay WH, Dennis JJ. Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections. *Antimicrob Agents Chemother*. 2014;58:4005–13. <https://doi.org/10.1128/AAC.02388-13>.
 50. Farina C, Boiron P, Goglio A, Provost F. Human nocardiosis in northern Italy from 1982 to 1992. *Scand J Infect Dis*. 1995;27:23–7. <https://doi.org/10.3109/00365549509018968>.
 51. Khan BA, Duncan M, Reynolds J, Wilkes DS. Nocardia infection in lung transplant recipients. *Clin Transplant*. 2008;22:562–6. <https://doi.org/10.1111/j.1399-0012.2008.00824.x>.
 52. Restrepo A, Clark NM. Nocardia infections in solid organ transplantation: guidelines from the infectious diseases community of practice of the American society of transplantation. *Clin Transplant*. 2019;33. <https://doi.org/10.1111/ctr.13509>.
 53. Hofmann P, Hombach M, Seifert B, Schuurmans MM, Bürgi U, Isenring B, et al. Isolation of Stenotrophomonas maltophilia in asymptomatic lung transplant recipients: effects of treatment on eradication and outcome. *Clin Transplant*. 2016;30:857–63. <https://doi.org/10.1111/ctr.12770>.
 54. Gallagher JC. Omadacycline: a modernized tetracycline. *Clin Infect Dis*. 2019;69:51–5. <https://doi.org/10.1093/cid/ciz394>.
 55. Yamano Y. *In vitro* activity of cefiderocol against a broad range of clinically important gram-negative bacteria. *Clin Infect Dis*. 2019;69:S544–51. <https://doi.org/10.1093/cid/ciz827>.
 56. Giannella M, Bartoletti M, Campoli C, Rinaldi M, Coladonato S, Pascale R, Tedeschi S, et al. The impact of carbapenemase-producing Enterobacteriaceae colonization on infection risk after liver transplantation: a prospective observational cohort study. *Clin Microbiol Infect*. 2019;25:1525–31. <https://doi.org/10.1016/j.cmi.2019.04.014>.
 57. Errico G, Gagliotti C, Monaco M, Masiero L, Gaibani P, Ambretti S, Landini MP, et al. Colonization and infection due to carbapenemase-producing Enterobacteriaceae in liver and lung transplant recipients and donor-derived transmission: a prospective cohort study conducted in Italy. *Clin Microbiol Infect*. 2019;25:203–9. <https://doi.org/10.1016/j.cmi.2018.05.003>.
 58. Parada MT, Alba A, Sepúlveda C. Early and late infections in lung transplantation patients. *Transplant Proc*. 2010;42:333–5. <https://doi.org/10.1016/j.transproceed.2009.12.002>.
 59. Kumar D, Husain S, Chen MH, Moussa G, Himsworth D, Manuel O, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. *Transplantation*. 2010;89:1028–33. <https://doi.org/10.1097/TP.0b013e3181d05a71>.
 60. Zamora MR. Cytomegalovirus and lung transplantation. *Am J Transplant*. 2004;4:1219–26.
 61. Razonable RR, Limaye AP. Cytomegalovirus infection after solid organ transplantation. *Am J Transplant*. 2013;13:93–106. <https://doi.org/10.1111/ajt.12103>.
 62. Yun JH, Lee SO, Jo KW, Choi SH, Lee J, Chae EJ, et al. Infections after lung transplantation: time of occurrence, sites, and microbiologic etiologies. *Korean J Intern Med*. 2015;30:506–14. <https://doi.org/10.3904/kjim.2015.30.4.506>.
 63. Humar A, Michaels M. American society of transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. *Am J Transplant*. 2006;6:262–74.
 64. Humar A, Snyderman D. Cytomegalovirus in solid organ transplant recipients. *Am J Transplant*. 2009;9.
 65. Kotton CN, Huprikar S, Kumar D. Transplant infectious diseases: a review of the scientific registry of transplant recipients published data. *Am J Transplant*. 2017;17:1439–46.
 66. Neuringer IP. Posttransplant lymphoproliferative disease after lung transplantation. *Clin Dev Immunol*. 2013.
 67. Kieff E. Epstein-Barr virus and its replication. *Fields Virol*. 2007:2603–54.
 68. Barkholt L, Linde A, Falk KI. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation. *Transpl Int*. 2005;18:835–43. <https://doi.org/10.1111/j.1432-2277.2005.00145.x>.
 69. Snyderman DR, Waggoner JJ, Soda EA, Deresinski S. Rare and emerging viral infections in transplant recipients. *Clin Infect Dis*. 2013;57:1182–8. <https://doi.org/10.1093/cid/cit456>.
 70. L'Huillier AG, Green M, Danziger-Isakov L, Chaudhuri A, Höcker B, Van der Linden D, et al. Infections among pediatric transplant candidates: an approach to decision-making. *Pediatr Transplant*. 2019;23. <https://doi.org/10.1111/petr.13375>.
 71. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. *Transplantation*. 2018;102:900–31. <https://doi.org/10.1097/TP.0000000000002191>.
 72. Harbell J, Terrault NA, Stock P. Solid organ transplants in HIV-infected patients. *Curr HIV/AIDS Rep*. 2013;10:217–25. <https://doi.org/10.1007/s11904-013-0170-z>.
 73. Kern RM, Seethamraju H, Blanc PD, Sinha N, Loebe M, Golden J, et al. The feasibility of lung transplantation in HIV-seropositive patients. *Ann Am Thorac Soc*. 2014;11:945–50. <https://doi.org/10.1513/AnnalsATS.201402-083OC>.
 74. Koval CE, Farr M, Krisl J, Haidar G, R Pereira M, Shrestha N, et al. Heart or lung transplant outcomes in HIV-infected recipients. *J Hear Lung Transplant*. 2019;38:1296–305. <https://doi.org/10.1016/j.healun.2019.09.011>.
 75. Englum BR, Ganapathi AM, Speicher PJ, Gulack BC, Snyder LD, Duane Davis R, et al. Impact of donor and recipient hepatitis C status in lung transplantation. *J Hear Lung Transplant*. 2016;35:228–35. <https://doi.org/10.1016/j.healun.2015.10.012>.
 76. Te H, Doucette K. Viral hepatitis: guidelines by the American society of transplantation infectious disease community of practice. *Clin Transplant*. 2019;33. <https://doi.org/10.1111/ctr.13514>.
 77. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm reports Morb Mortal Wkly Rep Recomm Rep*. 2006;55:1–48.
 78. Seem DL, Lee I, Umscheid CA, Kuehnert MJ. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. *Public Health Rep*. 2013;128:247–304.
 79. OPTN Policies Effective as of March 25 2021. Available at: https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf
 80. Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, et al. The American society of transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation. *Proc Am J Transpl*. 2017:2790–802.
 81. de Vera ME, Volk ML, Ncube Z, Blais S, Robinson M, Allen N, et al. Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV

- viremia. *Am J Transplant*. 2018;18:2451–6. <https://doi.org/10.1111/ajt.15031>.
82. Cypel M, Feld JJ, Galasso M, Pinto Ribeiro RV, Marks N, Kuczynski M, et al. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial. *Lancet Respir Med*. 2020;8:192–201. [https://doi.org/10.1016/S2213-2600\(19\)30268-1](https://doi.org/10.1016/S2213-2600(19)30268-1).
 83. Goldberg DS, Abt PL, Blumberg EA, Van Deerlin VM, Levine M, Reddy KR, et al. Trial of transplantation of HCV-infected kidneys into uninfected recipients. *N Engl J Med*. 2017;376:2394–5. <https://doi.org/10.1056/nejmc1705221>.
 84. Schlendorf KH, Zalawadiya S, Shah AS, Wigger M, Chung CY, Smith S, et al. Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies. *J Hear Lung Transplant*. 2018;37:763–9. <https://doi.org/10.1016/j.healun.2018.01.1293>.
 85. Fischer SA, Lu K. Screening of donor and recipient in solid organ transplantation. *Am J Transplant*. 2013;13:9–21. <https://doi.org/10.1111/ajt.12094>.
 86. White SL, Rawlinson W, Boan P, Sheppard V, Wong G, Waller K, et al. Infectious disease transmission in solid organ transplantation: donor evaluation, recipient risk, and outcomes of transmission. *Transplant Direct*. 2019;5.
 87. Fryer JF, Heath AB, Kessler H, Rawlinson W, Boivin G, Preiksaitis JK, Pang XL, et al. A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. *Biologicals*. 2016;44:242–51. <https://doi.org/10.1016/j.biologicals.2016.04.005>.
 88. Lisboa LF, Asberg A, Kumar D, Pang X, Hartmann A, Preiksaitis JK, et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. *Transplantation*. 2011;91:231–6. <https://doi.org/10.1097/TP.0b013e3181ff8719>.
 89. Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. Interlaboratory comparison of cytomegalovirus viral load assays. *Am J Transplant*. 2009;9:258–68. <https://doi.org/10.1111/j.1600-6143.2008.02513.x>.
 90. Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. *Ann Intern Med*. 2010;152:761–9. <https://doi.org/10.7326/0003-4819-152-12-201006150-00003>.
 91. Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. *Transplantation*. 2012;93:61–8. <https://doi.org/10.1097/TP.0b013e318238dab3>.
 92. Zuk DM, Humar A, Weinkauff JG, Lien DC, Nador RG, Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. *Transplantation*. 2010;90:672–6. <https://doi.org/10.1097/TP.0b013e3181ea3955>.
 93. Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. *Drugs*. 2010;70:965–81.
 94. Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. *Nephrol Dial Transplant*. 2012;27:2971–9. <https://doi.org/10.1093/ndt/gfr769>.
 95. Allen UD, Preiksaitis JK. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. *Am J Transplant*. 2013;13:107–20. <https://doi.org/10.1111/ajt.12104>.
 96. Lee DH, Zuckerman RA. Herpes simplex virus infections in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice. *Clin Transplant*. 2019;33. <https://doi.org/10.1111/ctr.13526>.
 97. Nosotti M, Tarsia P, Morlacchi LC. Infections after lung transplantation. *J Thorac Dis*. 2018;10:3849–68.
 98. Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Available online: <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm> (accessed on Nov 25, 2020).
 99. Levin MJ, Duchon JM, Swamy GK, Gershon AA. Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: varicella outcomes and safety results from a large, open-label, expanded-access program. *PLoS One*. 2019;14. <https://doi.org/10.1371/journal.pone.0217749>.
 100. NEW release: 7th edition Guide to the quality and safety of Organs for transplantation | EDQM - European Directorate for the Quality of Medicines Available online: <https://www.edqm.eu/en/news/new-release-7th-edition-guide-quality-and-safety-organs-transplantation> (accessed on Nov 25, 2020).
 101. Rohner E, Wyss N, Trelle S, Mbulaiteye SM, Egger M, Novak U, et al. HHV-8 seroprevalence: a global view. *Syst Rev*. 2014;3. <https://doi.org/10.1186/2046-4053-3-11>.
 102. Vu DL, Bridevaux PO, Aubert JD, Soccia PM, Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. *Am J Transplant*. 2011;11:1071–8. <https://doi.org/10.1111/j.1600-6143.2011.03490.x>.
 103. Allyn PR, Duffy EL, Humphries RM, Injean P, Weigt SS, Saggat R, et al. Graft loss and CLAD-onset is hastened by viral pneumonia after lung transplantation. *Transplantation*. 2016;100:2424–31. <https://doi.org/10.1097/TP.0000000000001346>.
 104. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, et al. Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. *Clin Infect Dis*. 2019;68:895–902.
 105. Razonable RR, Asberg A, Rollag H, Duncan J, Boisvert D, Yao JD, Caliendo AM, Humar A, Do TD. Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the world health organization international standard is predictive of CMV disease resolution in transplant recipients. *Clin Infect Dis*. 2013;56:1546–53. <https://doi.org/10.1093/cid/cit096>.
 106. Chou S, Marousek GI, Van Wechel LC, Li S, Weinberg A. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. *Antimicrob Agents Chemother*. 2007;51:4160–2. <https://doi.org/10.1128/AAC.00736-07>.
 107. Hakki M, Chou S. The biology of cytomegalovirus drug resistance. *Curr Opin Infect Dis*. 2011;24:605–11.
 108. Natori Y, Humar A, Husain S, Rotstein C, Renner E, Singer L, Kim SJ, Kumar D. Recurrence of CMV infection & the effect of prolonged antivirals in organ transplant recipients. *Transplantation*. 2017;101:1449–54. <https://doi.org/10.1097/TP.0000000000001338>.
 109. Gardiner BJ, Chow JK, Price LL, Nierenberg NE, Kent DM, Snyderman DR. Role of secondary prophylaxis with valganciclovir in the prevention of recurrent cytomegalovirus disease in solid organ transplant recipients. *Clin Infect Dis*. 2017;65:2000–7. <https://doi.org/10.1093/cid/cix696>.
 110. Sanford guide to antimicrobial therapy 2020 - pocket edition Available online: <https://store.sanfordguide.com/antimicrobial-therapy-2020-pocket-edition-4375-x-65-p151.aspx> (accessed on Oct 21, 2020).
 111. Nam HH, Ison MG. Respiratory syncytial virus infection in adults. *BMJ*. 2019; 366.
 112. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European conference on infections in leukaemia (ECIL-4): guidelines for diagnosis and treatment of human

- respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. *Clin Infect Dis*. 2013;56:258–66.
113. Foolad F, Aitken SL, Shigle TL, Prayag A, Ghantaji S, Ariza-Heredia E, Chemaly RF. Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients. *Clin Infect Dis*. 2019;68:1641–9. <https://doi.org/10.1093/cid/ciy760>.
 114. Zhou P, Yang X, Lou Wang XG, Hu B, Zhang L, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579:270–3. <https://doi.org/10.1038/s41586-020-2012-7>.
 115. Kumar D, Manuel O, Natori Y, Egawa H, Grossi P, Han SH, Fernández-Ruiz M, Humar A. COVID-19: a global transplant perspective on successfully navigating a pandemic. *Am J Transplant*. 2020;20:1773–9. <https://doi.org/10.1111/ajt.15876>.
 116. SARS-CoV-2 Vaccination in Heart and Lung Transplantation Recommendations from the ISHLT COVID-19 Task Force. Available at: https://ishlt.org/ishlt/media/Documents/COVID19_Vaccine-Recommendations_3-15-2021.pdf
 117. Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. *Am J Transplant*. 2020;20:1800–8. <https://doi.org/10.1111/ajt.15941>.
 118. Sharma P, Chen V, Fung CM, Troost JP, Patel VN, Combs M, et al. COVID-19 outcomes among solid organ transplant recipients: a case-control study. *Transplantation*. 2020. <https://doi.org/10.1097/TP.0000000000003447>.
 119. Tschopp J, L'Huillier AG, Mombelli M, Mueller NJ, Khanna N, Garzoni C, et al. First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. *Am J Transplant*. 2020;20:2876–82. <https://doi.org/10.1111/ajt.16062>.
 120. Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. *Am J Transplant*. 2020;20:1849–58. <https://doi.org/10.1111/ajt.15929>.
 121. Kates OS, Haydel BM, Florman SS, Rana MM, Chaudhry ZS, Ramesh MS, et al. Coronavirus disease 2019 in solid organ transplant: a multicenter cohort study. *Clin Infect Dis*. 2020. <https://doi.org/10.1093/cid/ciaa1097>.
 122. Saez-Giménez B, Berastegui C, Barrecheguren M, Revilla-López E, Los Arcos I, Alonso R, et al. COVID-19 in lung transplant recipients: a multicenter study. *Am J Transplant*. 2020. <https://doi.org/10.1111/ajt.16364>.
 123. Morlacchi LC, Rossetti V, Gigli L, Amati F, Rosso L, Aliberti S, et al. COVID-19 in lung transplant recipients: a case series from Milan, Italy. *Transpl Infect Dis*. 2020. <https://doi.org/10.1111/tid.13356>.
 124. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe covid-19. *N Engl J Med*. 2020. <https://doi.org/10.1056/NEJMoa2001282>.
 125. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19. *N Engl J Med*. 2020. <https://doi.org/10.1056/NEJMoa2007621>. *N. Engl. J. Med.*;382:2582, doi:10.1056/nejmc2021225.
 126. Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*. 2020;396:1345–52. [https://doi.org/10.1016/S0140-6736\(20\)32013-4](https://doi.org/10.1016/S0140-6736(20)32013-4).
 127. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. *N Engl J Med*. 2020;38:517–25. <https://doi.org/10.1056/nejmoa2016638>.
 128. Pathak DSK, Salunke DAA, Thivari DP, Pandey A, Nandy DK, Harish VK, et al. No benefit of hydroxychloroquine in COVID-19: results of systematic review and meta-analysis of randomized controlled trials. *Diabetes Metab Syndr Clin Res Rev*. 2020;14:1673–80. <https://doi.org/10.1016/j.dsx.2020.08.033>.
 129. Fabiani S, Fortunato S, Bruschi F. Solid organ transplant and parasitic diseases: a review of the clinical cases in the last two decades. *Pathogens*. 2018;7:65. <https://doi.org/10.3390/pathogens7030065>.
 130. Khemasuwan D, Farver C, Mehta AC. Parasitic diseases of the lung. in: *diseases of the central airways: a clinical guide*. Springer International Publishing; 2016. p. 231–53.
 131. Clark E, Pritchard H, Hemmige V, Restrepo A, Bautista K, Damania A, et al. Strongyloides stercoralis infection in solid organ transplant patients is associated with eosinophil activation and intestinal inflammation: a cross-sectional study. *Clin Infect Dis*. 2020;71:e580–6. <https://doi.org/10.1093/CID/CIAA233>.
 132. Riccardi N, Rotulo GA, Castagnola E. Definition of opportunistic infections in immunocompromised children on the basis of etiologies and clinical features: a summary for practical purposes. *Curr Pediatr Rev*. 2019;15:197–206. <https://doi.org/10.2174/1573396315666190617151745>.
 133. Cooper AJR, Dholakia S, Holland CV, Friend PJ. Helminths in organ transplantation. *Lancet Infect Dis*. 2017;17:e166–76.
 134. Buonfrate D, Gobbi F, Bisoffi Z. Helminths in organ transplantation. *Lancet Infect Dis*. 2017;17:581–2.
 135. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANS-NET). *Clin Infect Dis*. 2010;50:1101–11.
 136. Kennedy CC, Razonable RR. Fungal infections after lung transplantation. *Clin Chest Med*. 2017;38:511–20. <https://doi.org/10.1016/j.ccm.2017.04.011>.
 137. Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. *Medicine (Baltimore)*. 2011;90:69–80. <https://doi.org/10.1097/MD.0b013e318207612d>.
 138. Pérez-Cortés Villalobos A, Husain S. Infection prophylaxis and management of fungal infections in lung transplant. *Ann Transl Med*. 2020;8:414. <https://doi.org/10.21037/atm.2020.03.102>.
 139. Gavalda J, Meije Y, Fortún J, Roilides E, Saliba F, Lortholary O, Muñoz P, Grossi P, Cuenca-Estrella M. ESCMID study group for infections in compromised hosts. Invasive fungal infections in solid organ transplant recipients. *Clin Microbiol Infect*. 2014;20:27–48. <https://doi.org/10.1111/1469-0691.12660>.
 140. Cuenca-Estrella M, Verweij PE, Arendrup MC, et al. ESCMID. Guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. *Clin Microbiol Infect*. 2012;18:9–18.
 141. Pasqualotto AC, Xavier MO, Sánchez LB, de Oliveira Costa CD, Schio SM, Camargo SM, Camargo JJ, Sukiennik TC, Severo LC. Diagnosis of invasive aspergillosis in lung transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid. *Transplantation*. 2010;90:306–11. <https://doi.org/10.1097/TP.0b013e3181e49bc1>.
 142. Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos OC, et al. 5th European Conference on Infections in Leukemia (ECIL-5), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. *J Antimicrob Chemother*. 2016;71:2386–96. <https://doi.org/10.1093/jac/dkw156>.

143. Kato K, Nagao M, Nakano S, et al. Itraconazole prophylaxis for invasive aspergillus infection in lung transplantation. *Transpl Infect Dis.* 2014;16:340–3.
144. Robinson CL, Chau C, Yerkovich ST, Azzopardi M, Hopkins P, Chambers D. Posaconazole in lung transplant recipients: use, tolerability, and efficacy. *Transpl Infect Dis.* 2016;18:302–8. <https://doi.org/10.1111/tid.12497>.
145. Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. *Clin Infect Dis.* 2015;61:1558–65. <https://doi.org/10.1093/cid/civ571>.
146. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. *Lancet.* 2016;387:760–9. [https://doi.org/10.1016/S0140-6736\(15\)01159-9](https://doi.org/10.1016/S0140-6736(15)01159-9).
147. Samanta P, Clancy CJ, Marini RV, Rivosecchi RM, McCreary EK, Shields RK, et al. Isavuconazole is as effective as and better tolerated than voriconazole for antifungal prophylaxis in lung transplant recipients. *Clin Infect Dis.* 2020. <https://doi.org/10.1093/cid/ciaa652>.
148. Fontana L, Perlin DS, Zhao Y, Noble BN, Lewis JS, Strasfeld L, Hakki M. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. *Clin Infect Dis.* 2020;70:723–30. <https://doi.org/10.1093/cid/ciz282>. PMID: 30958538.
149. Fishman JA, Gans H. on behalf of the AST infectious diseases community of practice. Pneumocystis jirovecii in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice. *Clin Transpl.* 2019;33:e13587. <https://doi.org/10.1111/ctr.13587>.
150. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. *Clin Infect Dis.* 2016;63:e1–60.
151. Wang EH, Partovi N, Levy RD, Shapiro RJ, Yoshida EM, Greanya ED. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. *Transpl Infect Dis.* 2012;14:519–25. <https://doi.org/10.1111/j.1399-3062.2012.00740.x>.
152. Husain S, Camargo JF. Invasive Aspergillosis in solid-organ transplant recipients: Guidelines from the American society of transplantation infectious diseases community of practice. *Clin Transpl.* 2019;33:e13544.
153. Aslam S, Rotstein C, ASTIDCo Practice. Candida infections in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice. *Clin Transpl.* 2019;33:e13623.
154. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. *Clin Infect Dis.* 2010;50:291–322.